RSS Feed
January 25th, 2012 
FAKE NEWS for the Zionist agenda TUESDAY, Jan. 24 (HealthDay News) — Children with asthma who
don’t have heartburn and other signs of gastroesophageal reflux don’t get
additional asthma control from acid-reducing medications, according to new
research.
And, taking these medications when there are no digestive issues
increases a child’s risk of developing a respiratory infection, reports
the study.
“There’s a strong epidemiological link between acid reflux and asthma,”
explained study co-author Janet Holbrook, an associate professor of
epidemiology at the Johns Hopkins Bloomberg School of Public Health in
Baltimore. As a result, current asthma guidelines call for evaluating
people with asthma for acid reflux, Holbrook said.
Because definitive tests for excess acid production can cause children
discomfort, some doctors may choose to do a trial of acid-suppressing
medications called proton pump inhibitors (PPIs). Some common brand names
in this class of medication are Prilosec, Prevacid and Nexium.
“Our findings suggest that physicians should not take kids with poorly
controlled asthma and test whether PPIs will help,” said Holbrook.
Results of the study are published in the Jan. 25 issue of the
Journal of the American Medical Association. The study was funded
by the U.S. National Institutes of Health and conducted by the American
Lung Association Asthma Clinical Research Centers.
Asthma and gastroesophageal reflux (GER or GERD) are common conditions
in children. Youngsters with asthma often have symptoms of
gastroesophageal reflux. In adults, PPIs seem to help people with asthma
who also have symptoms of gastroesophageal reflux, but not those who don’t
have symptoms, such as frequent heartburn.
The current study included 306 children recruited from 19 centers
across the United States between 2007 and 2010. The average age was 11
years. All had poor asthma control despite receiving treatment with
inhaled corticosteroids.
The children were randomly assigned to receive either lansoprazole — a
PPI — or a placebo daily for six months. The dose of lansoprazole was
based on the child’s weight.
Asthma improvement was assessed through a change in the Asthma Control
Questionnaire, which has a scale of 0 to 6. A change of 0.5 is considered
clinically significant. Lung function was also measured.
After six months, there were no statistically significant differences
between the groups. The average change in the Asthma Control Questionnaire
score was only 0.2, and there were no statistically significant changes in
lung function, quality of life or rate of asthma flare-ups.
In addition, among 115 children who also had a 24-hour esophageal acid
study, 43 percent were found to have elevated levels of acid production.
Yet even in this group, treatment with lansoprazole didn’t improve asthma
symptoms over placebo.
Holbrook said although this study only looked at one PPI, she believes
the results would hold true for other medications in this class of drugs.
Children taking lansoprazole had about a 30 percent higher risk of
respiratory infections and sore throats in this study. PPIs were also
associated with a difference in the risk of activity-related bone
fractures, although the difference was not statistically significant,
according to an accompanying editorial in the same issue of the journal.
“PPIs do not improve asthma in children who do not have symptoms of
GER/GERD, and it is unlikely to be of great benefit even in children who
do have such symptoms,” said the editorial author, Dr. Fernando Martinez,
director of the Arizona Respiratory Center at the University of Arizona in
Tucson.
“The substantial increase in use of PPIs in children during the last
decade is worrisome and unwarranted,” he wrote.
Still, Martinez advised parents not to abruptly discontinue any
medications. Parents “should consult their pediatricians, who can best
evaluate the clinical situation for each child,” he said.
Holbrook agreed and said if a child is on a PPI, it’s reasonable for
parents to ask why. She noted that these medications may come with an
additional risk and cost, and they may not have any additional benefit.
“If your child is on a PPI for asthma, it’s not an effective treatment.
These medications are approved for the treatment of acid reflux,” said
Holbrook.
More information
Learn more about asthma treatment from the U.S. National Heart, Lung, and Blood Institute.
Related posts:
Views: 0
Posted in 
Tags: 
